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METHODS: Patients with an ACE between January 1, 2004 and May 31, 2009 were 
identiﬁ ed (the Index Date was deﬁ ned as the earliest ACE). Patients age ≥18, ≥6 
months eligibility pre- and post-Index Date, ≥1 statin ﬁ ll and no statin augmenting 
ﬁ ll 6 months before the Index Date, and ≥1 FF or SM ﬁ ll 6 months after the Index 
Date (Cohort ID Period) were included. Patients with ﬁ lls for alternative statin aug-
menting therapies or SCE during the Cohort ID Period were excluded. The primary 
outcome was SCE. Secondary outcomes were cerebrovascular event risk and event-
related medical costs. Event risk was compared using Cox proportional hazards 
models, while costs were compared via generalized linear models. Multivariate analy-
ses controlled for age, gender, geography, co-morbidities, concomitant medications, 
statin potency, and severity of initial ACE. RESULTS: A total of 24,625 patients added 
FF (n = 399) or maintained SM (n = 24,226) 6-months after initial ACE while meeting 
study inclusion/exclusion criteria. FF patients were younger (59 ± 10 vs. 65 ± 12, P < 
0.0001), less likely female (27% vs. 34%, P = 0.002), and had shorter follow-up (358 
vs. 443 days, P < 0.0001). FF patients had lower frequency of SCE (20%) vs. SM 
(25%), with an unadjusted hazard ratio (HR) of 0.88 (95%CI: 0.71–1.10). a similar 
directional trend was observed for cerebrovascular events (HR: 0.74; 95% CI: 0.40–
1.37). Multivariate analyses of SCE risk demonstrated consistent directional beneﬁ t 
(HR: 0.93; 95% CI: 0.74–1.16). Clinical ﬁ ndings corresponded with 25% lower 
adjusted annual event-related costs compared to SM (0.75; 95% CI: 0.57—0.97; p = 
0.0306). CONCLUSIONS: The positive clinical beneﬁ ts from this real-world analysis 
provide evidence supporting ability of FF to reduce both SCE risk and event-related 
medical costs following ACE.
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OBJECTIVES: The aims of study were 1)to determine equivalent dosages of 
Rosuvastin(R) and Atorvastatin(A) in the treatment of dyslipidemia, and 2)to evaluate 
cost-effectiveness of R vs. A. METHODS: The R and a arms of 29 RCTs with stable 
dose treatments for minimum 6 weeks (n = 27.588) were included in the analysis. The 
arms with periods after titration or switch were excluded. The effectiveness parameters 
chosen were the pooled percent decrease in LDL-C, LDL/HDL, TC/HDL ratios and 
10-years’ cardiovascular risk (CVR) based on Wilson equation. Only medication costs 
were calculated for R and A, since other costs directly related with dyslipidemia were 
assumed to be same. Dose-effect relationship was analyzed by plotting linear regres-
sion line for R and A, separately. Incremental Cost-effectiveness Ratios (ICER) were 
calculated as added cost per percent decrease in lipid parameters and per absolute 
reduction in 10-years’ CVR. RESULTS: Equivalent clinical effectiveness of R was 
provided with 3.9-fold, 3.2-fold and 3.2-fold dosages of a in mg, in terms of percent 
decrease in LDL-C, LDL/HDL and TC/HDL ratios, respectively. Absolute 10-years’ 
CVR reductions with R5-40 mg and A10-80 mg were 4.5–6.9% and 3.7–5.7%, 
respectively. 1(R):2(A) dose pair was selected for cost-effectiveness analysis. The yearly 
medication costs were as follows: R5 mg vs. A10 mg (c113.67** vs. c128.03), 
R10 mg vs. A20 mg (c174.68 vs. 226.77c), R20 mg vs. A40 mg (c261.26 vs. 283.20c) 
and R40 mg vs. A80 mg (c261.26 vs. c294.68). R dominated a with regards to ICER 
for all effectiveness parameters. Sensitivity analysis proved that dominance of R was 
stable when the model was run for extreme values for R and a in the literature. 
CONCLUSIONS: In this analysis, R was found more efﬁ cacious than three times 
higher dose of A. R is more cost-effective than a in reducing LDL-C level, LDL-HDL 
and TC/HDL ratios and 10-years’ CVR reduction. **1 Euro = 1.9595TL
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OBJECTIVES: The objective of this study was to quantify, for the ﬁ rst time in a 
Spanish population, the time and cost burden of informal care for patients with heart 
failure. METHODS: A descriptive analysis of a multicenter, prospective observational 
study was performed. Patients who met inclusion criteria were followed-up for a 
period of 12 months, with 3 visits programmed at baseline, 6 months and 12 months. 
a total of 9 Spanish hospitals were involved in the study. Baseline characteristics and 
caregiver’s information were registered for every patient. Once identiﬁ ed total hours, 
the replacement cost method was used. RESULTS: A total of 450 patients were 
included, 76% men, mean age was 62.6 years. 66.1% were in NYHA class II, 32.7% 
NYHA class III and 1.1% NYHA class IV. Prevalence of ischemic cardiopathy was 
33.5%. Thirty-ﬁ ve percent of patients had an implantable device (ICD, RCT or 
pacemaker). One-third needed support for daily activities. One-hundred and one 
informal caregivers were identiﬁ ed, mean age of 57.6 years, mostly women (84.1%). 
Main relationship with caregiver was spouse/couple (74.2%), followed by son/daugh-
ter (16.6%). Number of weekly hours of caregiving was estimated at 42.5 hours 
(39.46 hours for patients NYHA class II and 47.39 hours for patients NYHA class 
III-IV) and shadow prices values from c9 to c12 per hour. Total costs associated to 
informal caregiving increases between c19,897 and c26,530 (c18,466–c24,621 for 
patients in NYHA class II and c22,178–c29,571 for patients in NYHA class III or 
IV). CONCLUSIONS: Approximately one-third required support from an informal 
caregiver, which represents a signiﬁ cant burden for society and often has not been 
accounted for in economic evaluations of treatments for heart failure. Costs for 
informal care appear to increase with worse disease severity as measured by NYHA 
class.
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OBJECTIVES: Acute coronary syndrome (ACS) is a highly prevalent disease and the 
third-leading cause of death in Korea, however the economic impact of ACS from 
societal perspective has not been investigated. This study examined the national epi-
demiology and economic costs of ACS in Korea for 2009. METHODS: This study 
used the societal cost of illness framework, consisting of epidemiology of ACS, direct 
medical costs, direct non-medical costs, and indirect costs such as productivity lost 
from morbidity and mortality of ACS. National-level health survey results and insur-
ance claim databases were used to analyze annual health care utilization, hospitaliza-
tion costs and outpatient costs of the total Korean population (48 million people). 
Using a data mining technique, we identiﬁ ed medical claims with international clas-
siﬁ cation of disease 10 codes for ACS over a one year period and estimated the costs 
by a macro-costing method. RESULTS: Prevalence rate of ACS is estimated at 6.4 
persons per 1000 population in 2009 and its mortality rate is 7.8% in 2008. During 
2009, there were 309,384 patients who had at least 1 medical claim related to ACS. 
The total societal cost of ACS in 2009 was estimated at $1.02 billion. Direct medical 
cost for ACS was $380.3 million, which includes hospitalization cost of $318.8 million 
and outpatient cost of $61.6 million. The direct non-medical cost, involving transpor-
tation cost and caregiver cost, was estimated at $10.1 million. Indirect costs associated 
with morbidity and mortality of ACS were $627.2 million. CONCLUSIONS: The 
study showed that the societal cost of ACS in Korea is markedly high, particularly the 
indirect cost, followed by hospitalization cost. Early and effective management of the 
disease is necessary to reduce mortality and morbidity of ACS. Findings of this study 
suggest for further research to uncover ways to reduce the economic burden of ACS 
in Korea.
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OBJECTIVES: Aneurysmal subarachnoid hemorrhage (SAH) is a cerebrovascular 
disease with a high mortality and severe disability. Longitudinal studies investigating 
health-economic burden and health-related quality of life (HRQoL) in SAH are scare 
and only one previous study analyzed cost-driving factors. The objective was to evalu-
ate HRQoL and ﬁ rst-year costs in German patients with aneurysmal SAH and to 
identify cost-driving factors. METHODS: A total of 113 incident cases of aneurysmal 
SAH treated in the Department of Neurosurgery and Neuroradiology at the University 
of Bonn between January 2004 and December 2005 were eligible for the study. Clini-
cal assessments (Hunt and Hess scale, Barthel Index), evaluation of HRQol (36-Item 
Short Form Survey, EQ5D, EQ-VAS) and collection of cost data from societal perspec-
tive (health-economic questionnaires) were performed at discharge, and at 6 and 12 
months follow-up. All costs are expressed in c (year 2009 values). Independent deter-
minants of costs and HRQoL were identiﬁ ed using multiple regression analysis. 
RESULTS: The total ﬁ rst-year costs were c38,300 (95%CI: 34,490–43,100) per 
patient. Direct costs accounted for 58.7% of total costs and were mainly paid by the 
health insurance (92.0%). The major cost-driving factors were younger age and worse 
functional outcome (Barthel-Index). HRQol in SAH patients was considerably 
reduced. At discharge, 92.2% of patients had moderate or severe problems on the 
EQ-5D. The EQ-VAS at discharge was 57.8 ± 19.3 and increased by only 12–14% 
after 12 months. Independent predictors of decreased HRQol were female gender, 
severe disease, depression, lower level of education and the lack of a stable partnership. 
CONCLUSIONS: Aneurysmal SAH is a cerebrovascular disease with considerable 
health-economic burden and unfavourable long-term HRQoL outcome. Clinical trials 
in SAH should include HRQol measures. Independent determinants of costs and 
HRQol identiﬁ ed in this study should be considered in the health care programmes 
aimed at increasing the HRQol in SAH survivors and decreasing health-economic 
burden of SAH.
